A survey of 1,700 Americans 45 and older found that 79% would want to know if they were in the early stages of Alzheimer's disease.

A new generation of blood tests can help doctors diagnose Alzheimer's without a brain scan or spinal tap. But only a few perform as well as traditional tests.

In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.

The first drug found to slow the progression of Alzheimer's disease has been granted full approval by the Food and Drug Administration.

The Food and Drug Administration is expected to grant full approval to the Alzheimer's drug lecanemab by July 6. But access to the drug may still be limited.

An Alzheimer's drug that removes the substance amyloid from the brain has received a conditional approval from the FDA. A large study found the drug decreased the loss of thinking and memory by 27%.

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.